全球寡核苷酸合成市场

全球寡核苷酸合成市场预计到2030年将达到199亿美元

2024年全球寡核苷酸合成市场规模估计为83亿美元，预计在分析期间（2024-2030年）将以15.6%的复合年增长率增长，到2030年将达到199亿美元。本报告分析的细分市场之一－基于寡核苷酸的药物，预计将以17.3%的复合年增长率成长，到分析期末将达到86亿美元。合成寡核苷酸细分市场预计在分析期间将以15.0%的复合年增长率成长。

美国市场规模估计为22亿美元，中国市场预计将以21.2%的复合年增长率成长。

预计到2024年，美国寡核苷酸合成市场规模将达22亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到49亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到21.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，这两个市场的复合年增长率将分别达到11.1%和13.1%。在欧洲，德国的复合年增长率预计将达到约12.2%。

全球寡核苷酸合成市场—主要趋势与驱动因素概述

什么是寡核苷酸合成？为什么它引起了全世界的关注？

寡核苷酸合成是指用于建构短核苷酸序列（DNA和RNA的基本组成单元）的化学过程。这些合成寡核苷酸对于从诊断和治疗到基因研究和生物技术等多种应用至关重要。透过合成过程客製化DNA和RNA链的能力彻底改变了分子生物学，使研究人员能够设计特定的序列用于标靶基因介入、基因编辑和药物开发。寡核苷酸在现代生物技术中发挥关键作用，支持PCR（聚合酵素链锁反应）、DNA序列测定、基因合成和反义核酸治疗药物等应用。作为一项关键的实行技术，寡核苷酸合成为基因组学、个人化医疗和药物发现领域的突破奠定了基础，使其成为生命科学和医疗保健领域不可或缺的一部分。

科技如何推动寡核苷酸合成的发展？

技术进步在寡核苷酸合成的发展历程中发挥了关键作用，显着提高了生产过程的精确度、可扩展性和效率。自动化合成仪和改进的固相合成方法等创新技术大大加快了寡核苷酸的生产速度，使其更容易满足製药和生物技术行业日益增长的需求。此外，高通量合成技术的最新进展使得大规模寡核苷酸库的平行生产成为可能，从而推动了基因编辑和CRISPR技术等领域的快速研究。次世代定序仪（NGS）技术的出现进一步增加了对高品质寡核苷酸的需求，因为精确的客製化序列在NGS工作流程中至关重要。各公司正投入大量资金提高合成寡核苷酸的纯度、长度和序列保真度，不断拓展基因研究和分子诊断领域的应用边界。

为什么寡核苷酸对治疗和诊断至关重要？

人们对寡核苷酸在治疗和诊断应用方面的兴趣日益浓厚，这是推动市场发展的关键因素。在治疗领域，寡核苷酸被用于建构反义寡核苷酸（ASO）、小干扰RNA（siRNA）和适配体，这些分子均能调节基因表现和蛋白质功能。目前，这些治疗方法正被研究用于治疗遗传性疾病、癌症和罕见疾病，为人们提供了一类新型的高标靶化、个人化药物。此外，在诊断领域，合成寡核苷酸对于开发用于检测基因突变、病原体和生物标记的检测方法至关重要。例如，新冠肺炎疫情凸显了寡核苷酸在诊断测试（如PCR检测）开发中的关键作用，这些测试依赖于短的、客製化设计的DNA引子。基因治疗、免疫疗法和精准医疗的快速发展，正在催生对客製化寡核苷酸合成服务的强劲需求，进一步巩固了该技术在推动医疗保健发展中的作用。

推动寡核苷酸合成市场成长的关键因素是什么？

寡核苷酸合成市场的成长受多种因素驱动，每个因素都对市场扩张做出独特的贡献。其中一个关键因素是治疗药物研发，特别是针对罕见疾病和复杂疾病的基因疗法，合成寡核苷酸的需求不断增加。 CRISPR和基因编辑技术的快速发展也推动了对高品质寡核苷酸的需求，这些寡核苷酸可用作引导RNA和其他基因操作的关键组件。个人化医疗领域的不断发展，根据患者的个别基因谱量身订做治疗方案，进一步推动了对客製化寡核苷酸合成的需求。此外，次世代定序仪和分子诊断技术的广泛应用也显着扩大了用于诊断检测和研究的寡核苷酸市场。自动化和高通量合成等製造技术的进步，使企业能够以更低的成本更有效率地生产寡核苷酸，从而使更多研究人员和製药公司能够获得寡核苷酸。在可预见的未来，对生物技术的持续投资和对基因组学日益增长的兴趣预计将支撑该市场的强劲成长。

部分

产品（基于寡核苷酸的药物、合成寡核苷酸、试剂、器械）、应用（治疗、诊断、研究）、最终用途（医院、诊断实验室、製药和生物技术公司、其他最终用途）

受访公司范例

• ATDBio Ltd.
• Bio-Synthesis Inc.
• Eurogentec
• GE Healthcare Life Sciences
• GeneDesign, Inc.
• GenScript Biotech Corporation
• Integrated DNA Technologies（IDT）, Inc.
• LGC Biosearch Technologies
• Merck KgaA
• Nitto Denko Avecia Inc.
• Thermo Fisher Scientific, Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具，革新市场和竞争情报。

全球行业分析师并没有遵循典型的LLM或特定行业的SLM查询，而是建立了一个内容库，其中收集了来自世界各地专家的信息，包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师预测，企业的竞争地位将根据其总部所在国家、製造地以及进出口（成品和OEM）情况而改变。这种复杂多变的市场动态预计将从多个方面影响竞争对手，包括销货成本成本上升、盈利下降以及供应链重组等，以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 澳洲
• 印度
• 韩国
• 亚太其他地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Oligonucleotide Synthesis Market to Reach US$19.9 Billion by 2030

The global market for Oligonucleotide Synthesis estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.9 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Oligonucleotide-Based Drugs, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Synthesized Oligonucleotides segment is estimated at 15.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 21.2% CAGR

The Oligonucleotide Synthesis market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 21.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Oligonucleotide Synthesis Market - Key Trends & Drivers Summarized

What Is Oligonucleotide Synthesis and Why Is It Gaining Global Attention?

Oligonucleotide synthesis refers to the chemical process used to create short sequences of nucleotides, the building blocks of DNA and RNA. These synthetic oligonucleotides are essential for a variety of applications, ranging from diagnostics and therapeutics to genetic research and biotechnology. The ability to custom-build DNA or RNA strands through synthetic processes has revolutionized molecular biology, allowing researchers to design specific sequences for targeted genetic interventions, gene editing, and pharmaceutical development. Oligonucleotides play a crucial role in modern biotechnology, supporting applications such as PCR (polymerase chain reaction), DNA sequencing, gene synthesis, and antisense therapeutics. As a key enabling technology, oligonucleotide synthesis underpins breakthroughs in genomics, personalized medicine, and drug discovery, making it indispensable to life sciences and healthcare.

How Is Technology Shaping the Evolution of Oligonucleotide Synthesis?

Technological advancements have been pivotal in the evolution of oligonucleotide synthesis, driving higher precision, scalability, and efficiency in the production process. Innovations such as automated synthesizers and improved solid-phase synthesis methods have significantly accelerated the rate at which oligonucleotides can be manufactured, making it easier to meet the growing demands of pharmaceutical and biotechnology industries. Additionally, recent developments in high-throughput synthesis technology allow for the parallel production of large libraries of oligonucleotides, enabling faster research in fields like gene editing and CRISPR technology. The advent of next-generation sequencing (NGS) technologies has further heightened the need for high-quality oligonucleotides, as precise and custom-designed sequences are critical for NGS workflows. Companies are investing heavily in enhancing the purity, length, and sequence fidelity of synthesized oligonucleotides, pushing the boundaries of what can be achieved in genetic research and molecular diagnostics.

Why Are Oligonucleotides Essential in Therapeutics and Diagnostics?

The rising interest in oligonucleotides for therapeutic and diagnostic applications has been a significant driver for the market. In therapeutics, oligonucleotides are used to create antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, all of which can modulate gene expression or protein function. These therapies are being explored for the treatment of genetic disorders, cancers, and rare diseases, offering a new class of drugs that are highly targeted and personalized. Additionally, in diagnostics, synthetic oligonucleotides are critical in the development of assays for detecting genetic mutations, pathogens, and biomarkers. The COVID-19 pandemic, for example, highlighted the critical role of oligonucleotides in the development of diagnostic tests such as PCR assays, which rely on short, custom-designed DNA primers. The rapid expansion of gene therapy, immunotherapy, and precision medicine has created a robust demand for custom oligonucleotide synthesis services, further cementing the role of this technology in advancing healthcare.

What Are the Major Drivers Fueling the Growth of the Oligonucleotide Synthesis Market?

The growth in the oligonucleotide synthesis market is driven by several factors, each contributing uniquely to its expansion. One of the primary drivers is the increasing demand for synthetic oligonucleotides in therapeutic development, particularly for genetic therapies aimed at treating rare and complex diseases. The rapid rise of CRISPR and gene-editing technologies has also fueled the need for high-quality oligonucleotides that can be used as guide RNAs and other components essential for gene manipulation. The growing field of personalized medicine, where treatments are tailored to the genetic profile of individual patients, is further driving the demand for custom oligonucleotide synthesis. Additionally, the widespread adoption of next-generation sequencing and molecular diagnostics has significantly expanded the market for oligonucleotides used in diagnostic assays and research. With advancements in manufacturing technologies, including automation and high-throughput synthesis, companies can now produce oligonucleotides more efficiently and at lower costs, making them accessible to a broader range of researchers and pharmaceutical companies. The continued investment in biotechnology, coupled with an increasing focus on genomics, is expected to sustain robust growth in this market for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Oligonucleotide Synthesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Equipment); Application (Therapeutics, Diagnostics, Research); End-Use (Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• ATDBio Ltd.
• Bio-Synthesis Inc.
• Eurogentec
• GE Healthcare Life Sciences
• GeneDesign, Inc.
• GenScript Biotech Corporation
• Integrated DNA Technologies (IDT), Inc.
• LGC Biosearch Technologies
• Merck KgaA
• Nitto Denko Avecia Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Oligonucleotide Synthesis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Custom Oligonucleotides in Research and Diagnostics Propels Growth of the Oligonucleotide Synthesis Market Globally
  • Increased Focus on Gene Editing Technologies, Including CRISPR, Drives the Adoption of Advanced Oligonucleotide Synthesis Techniques
  • Growing Investment in Genomics and Proteomics Research Expands the Addressable Market Opportunity for Oligonucleotide Synthesis Services
  • Surging Use of Oligonucleotides as Therapeutic Agents in Oncology and Rare Diseases Spurs Growth in Oligonucleotide Synthesis
  • Technological Advancements in Automated and High-Throughput Oligonucleotide Synthesizers Propel Efficiency and Accelerate Market Growth
  • Rising Interest in Personalized Medicine and Precision Therapies Strengthens the Business Case for Oligonucleotide Synthesis in Clinical Applications
  • Increased Adoption of Oligonucleotides in Molecular Diagnostics and Pathogen Detection Generates Demand for Efficient Synthesis Platforms
  • Growing Demand for Antisense Oligonucleotides and siRNA Therapeutics Creates New Opportunities for Oligonucleotide Synthesis Providers
  • Expansion of Gene Therapy and Vaccine Development Using Synthetic Oligonucleotides Drives Long-Term Growth in the Market
  • Increasing Use of Oligonucleotides in Agricultural Biotechnology Expands Market Opportunities Beyond
  • Enhanced Stability and Delivery Technologies for Oligonucleotides Propel Growth in Therapeutic Applications
  • Stringent Regulatory Requirements for Oligonucleotide Synthesis in Therapeutics and Diagnostics Create Challenges and Drive Innovation in Quality Control
  • The Growing Shift Toward Synthetic Biology and DNA Data Storage Systems Generates Demand for High-Fidelity Oligonucleotide Synthesis
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oligonucleotide Synthesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oligonucleotide-Based Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Synthesized Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION